MRT Stock Recent News

ISTANBUL--(BUSINESS WIRE)--Marti Technologies, Inc. (“Marti” or the “Company”) (NYSE American: MRT), Türkiye's leading mobility super app, announced today that as of March 25, 2025, Marti's ride-hailing service has reached 1.91 million riders and 290 thousand registered drivers, exceeding the March 31, 2025 targets of 1.90 million riders and 290 thousand registered drivers. Marti's number of ride-hailing riders grew 18.6% from December 15, 2024 to March 25, 2025. The number of registered driver.

ISTANBUL--(BUSINESS WIRE)--Türkiye's leading mobility super app Marti Technologies, Inc. (“Marti” or the “Company”) (NYSE American: MRT) today announced an amendment to extend its share repurchase program. The Company's Board of Directors (the “Board”) authorized a six month extension to its share repurchase program under which the Company may repurchase up to $2.5 million of its outstanding Class A ordinary shares until October 9, 2025. The share repurchase program was originally initiated on.

Results of the MRT-6160 Phase 1 SAD/MAD study demonstrate deep VAV1 degradation of greater than 90%, significant T and B cell functional inhibition as well as significant inhibition of cytokine release from T and B cells following ex-vivo stimulation, and favorable safety/tolerability profile; data support clear path to Phase 2 studies and broad potential applications in immune-mediated diseases Phase 1/2 study of MRT-2359 demonstrates encouraging signals of clinical response in castration-resistant prostate cancer (CRPC) patients resistant to AR therapy, including confirmed RECIST response; CRPC cohort will be focus moving forward with additional Phase 1/2 results expected in H2 2025; deprioritizing further expansion arms in SCLC, NSCLC and NE tumors MRT-8102, a NEK7-directed molecular glue degrader targeting diseases driven by IL-1β and the NLRP3 inflammasome, on track for IND filing in H1 2025 Strong cash position expected to fund operations into 2028 through multiple anticipated p

One of Monte Rosa Therapeutics' main differentiating factors is its proprietary QuEEN platform to design new molecular glue degraders. This process also leverages AI. They now have two important partnerships with Roche and Novartis, which I think validate its technology to some extent, but have also given it non-dilutive funding. Currently, its pipeline has MRT‑2359, MRT‑6160, and MRT‑8102, with key data expected in 2025.

Morguard Real Estate Investment Trust (OTC:MGRUF) Q4 2024 Earnings Conference Call February 13, 2025 4:00 PM ET Company Participants Andrew Tamlin - Chief Financial Officer John Ginis - Assistant Vice President, Retail Asset Management Tom Johnston - Senior Vice President of Western Asset Management Todd Febbo - Vice President, Eastern Office Management Conference Call Participants Jonathan Kelcher - TD Cowen Roger Lafontaine - Nugget Capital Markets Andrew Tamlin Good afternoon, everyone. My name is Andrew Tamlin, Chief Financial Officer of Morguard REIT.